Background:
The approval of Libtayo (Cemiplimab-rwlc) by the FDA has marked the start of a new drug protocol that can help lung cancer patients. This is a huge breakthrough in the world of medicine especially in the branch of cancer research since lung cancer is the most common in the world. In fact, it is the leading cancer killer in both men and women including breast cancer. Every year, there are nearly two million cases of lung cancer and nearly 1.4 million cases of death. Not only that, but this cancer also has a lot of long-term side effects that can linger with difficult cases.
However, cancer research is always looking for ways to find treatments that can increase the survival rate and decrease the recovery time. This time, it looks like they struck gold with adding Cemiplimab to Chemo. The combination has been so successful that they did not have to continue the research because there had been significant improvements in the survival rates.
The significance of the study:
Researchers looked at the effects of Cemiplimab-rwlc (Libtayo) plus platinum chemotherapy for patients diagnosed with locally advanced or metastatic non–small cell lung cancer (NSCLC). The results show that the median survival was 22.1 months with the Cemiplimab-rwlc which was significantly higher than the 14.3-months survival of the chemotherapy-only group.
Additionally, the group that took the Cemiplimab chemo combo had a much longer time until their disease has progressed again, much better tumor control, longer duration of response, improved quality of life, as well as less side effects.
Cemiplimab-rwlc, Libtayo, is an immunotherapy, a monoclonal antibody, against PD-1.
What this means for lung cancer patients:
There is no denying that lung cancer is quite grim. The survival rates as well recovery for these patients is always tough. However, we have good news ahead with the approval of Libtayo (Cemiplimab-rwlc) combo with platinum chemotherapy. For patients whose cancer is advanced, Cemiplimab is an excellent first line of treatment since it has been shown to be effective at increasing survival.
Conclusion:
With the approval of Cemiplimab by the European Medicines Agency and the FDA, patients who suffer from lung cancer and their loved ones can finally take a sigh of relief. Moreover, Cemiplimab and chemotherapy combination is also safe for adults.
Talk to us so see if we can help you to actually get the most advanced treatments
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039
